nsv491541
- Organism: Homo sapiens
- Study:nstd45 (ClinGen Curated Dosage Sensitivity Map-obsoleted)
- Variant Type:copy number variation
- Method Type:
- Submitted on:GRCh37 (hg19)
- Variant Calls:0
- Validation:Not tested
- Clinical Assertions: No
- Region Size:16,114
- Description:PLP1; Though this gene was evaluated in the context of Pelizaeus-Merzbacher disease (OMIM:312080), the gene has also been implicated in spastic paraplegia type 2.
- Publication(s):Riggs et al. 2011
- Genome View
- Variant Region Details and Evidence
- Validation Information
- Clinical Assertions
- Genotype Information
Genome View
Select assembly:Overlapping variant regions from other studies: 291 SVs from 26 studies. See in: genome view
Overlapping variant regions from other studies: 293 SVs from 26 studies. See in: genome view
Variant Region Placement Information
Variant Region ID | Placement Type | Score | Assembly | Assembly Unit | Reciprocity | Sequence ID | Chr | Inner Start | Inner Stop |
---|---|---|---|---|---|---|---|---|---|
nsv491541 | Remapped | Good | GRCh38.p12 | Primary Assembly | First Pass | NC_000023.11 | ChrX | 103,776,506 | 103,792,619 |
nsv491541 | Submitted genomic | GRCh37 (hg19) | Primary Assembly | NC_000023.10 | ChrX | 103,031,434 | 103,047,548 |
Variant Call Information
Variant Call ID | Type | Method | Analysis | Subject Phenotype | Clinical Interpretation | Source of Interpretation | Copy number |
---|---|---|---|---|---|---|---|
nssv1184594 | copy number loss | Curated | Curated | PELIZAEUS-MERZBACHER DISEASE; PMD; SPASTIC PARAPLEGIA 2, X-LINKED; SPG2 | Pathogenic | ClinGen Dosage Sensitivity Map | 0 |
nssv1184595 | copy number gain | Curated | Curated | PELIZAEUS-MERZBACHER DISEASE; PMD | Pathogenic | ClinGen Dosage Sensitivity Map | 2 |
Variant Call Placement Information
Variant Call ID | Placement Type | Score | HGVS | Assembly | Reciprocity | Sequence ID | Chr | Inner Start | Inner Stop |
---|---|---|---|---|---|---|---|---|---|
nssv1184594 | Remapped | Good | NC_000023.11:g.(?_ 103776506)_(103792 619_?)del | GRCh38.p12 | First Pass | NC_000023.11 | ChrX | 103,776,506 | 103,792,619 |
nssv1184595 | Remapped | Good | NC_000023.11:g.(?_ 103776506)_(103792 619_?)dup | GRCh38.p12 | First Pass | NC_000023.11 | ChrX | 103,776,506 | 103,792,619 |
nssv1184594 | Submitted genomic | NC_000023.10:g.(?_ 103031434)_(103047 548_?)del | GRCh37 (hg19) | NC_000023.10 | ChrX | 103,031,434 | 103,047,548 | ||
nssv1184595 | Submitted genomic | NC_000023.10:g.(?_ 103031434)_(103047 548_?)dup | GRCh37 (hg19) | NC_000023.10 | ChrX | 103,031,434 | 103,047,548 |
No validation data were submitted for this variant
Clinical Assertions
Variant Call ID | HGVS | Type | Subject Phenotype | Clinical Interpretation | Source of Interpretation | Copy number |
---|---|---|---|---|---|---|
nssv1184594 | GRCh37: NC_000023.10:g.(?_103031434)_(103047548_?)del | copy number loss | PELIZAEUS-MERZBACHER DISEASE; PMD; SPASTIC PARAPLEGIA 2, X-LINKED; SPG2 | Pathogenic | ClinGen Dosage Sensitivity Map | 0 |
nssv1184595 | GRCh37: NC_000023.10:g.(?_103031434)_(103047548_?)dup | copy number gain | PELIZAEUS-MERZBACHER DISEASE; PMD | Pathogenic | ClinGen Dosage Sensitivity Map | 2 |